<DOC>
	<DOCNO>NCT02374164</DOCNO>
	<brief_summary>The purpose study assess effect food bioavailability febuxostat single oral dose 80 mg febuxostat XR evaluate pharmacokinetics ( PK ) febuxostat single oral dos 40 80 mg febuxostat XR .</brief_summary>
	<brief_title>Food Effect Study Febuxostat XR Healthy Participants</brief_title>
	<detailed_description>The drug test study call febuxostat extended- release ( XR ) . This study evaluate effect food febuxostat-XR move throughout body . This study also look side effect safety result people take study drug . This 3-way crossover study enroll approximately 36 participant . Eligible participant randomly ( chance ) assign one 3 treatment sequence 1:1:1 ratio . Sequence defines order participant receive Regimens A ( febuxostat XR 80 mg high fat meal ) , B ( febuxostat XR 40 mg fasting ) C ( febuxostat XR 80 mg fast ) : Sequence 1 : A , B , C Sequence 2 : B , C , A Sequence 3 : C , A , B The dose period dose subsequent period separate minimum 7-day washout interval . This single-centre trial conduct United States . Participants make multiple visit clinic include three 4-day period confinement clinic , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . Has estimate glomerular filtration rate â‰¥90 mL/min . 2 . Weighs least 50 kg ( 110 pound ) body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive , Screening . 3 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 4 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose . 5 . Able attend visit schedule study . 6 . Willing refrain strenuous exercise Day 1 Study Exit ( Day 3 Period 3 ) . 1 . Hypersensitivity Febuxostat component formulation . 2 . Has receive investigational compound within 30 day prior first dose study medication . 3 . Has receive febuxostat previous clinical study therapeutic agent . 4 . Has uncontrolled , clinically significant disease abnormality , may impact ability participant participate potentially confound study result . 5 . Has know hypersensitivity xanthine oxidase ( XO ) inhibitor , xanthine compound , Febuxostat component formulation Febuxostat tablet , caffeine . 6 . Has positive urine drug result drug abuse Screening Checkin ( Day 1 Period 1 ) . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . 8 . Is pregnant lactate intend become pregnant , , within 30 day post last dose ; intend donate ova time period . 9 . Intends impregnate others donate sperm course study 30 day post last dose . 10 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma , hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take febuxostat XR , similar drug class , disease might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 11 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention [ eg , cholecystectomy ] ) . 12 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 Period 1 . 13 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody know history human immunodeficiency virus infection . 14 . Has use nicotinecontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 28 day prior Checkin ( Day 1 Period 1 ) unwilling agree abstain nicotinecontaining product . Cotinine test positive Screening Checkin ( Day 1 Period 1 ) . 15 . Has poor peripheral venous access . 16 . Has donate lose 450 mL blood volume ( include plasmapheresis ) transfusion blood product within 30 day prior Day 1 Period 1 . 17 . Has Screening abnormal ( clinically significant ) electrocardiogram ( ECG ) . 18 . Has abnormal Screening Day 1 Period 1 laboratory value suggest clinically significant underlying disease participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 x upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>